Related Experiment Video
Updated: Jun 27, 2026
10:50
Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
Monoclonal antibodies--regulatory challenges.
1Paul-Ehrlich-Institut, D-63225 Langen, Germany. schci@pei.de
Current Pharmaceutical Biotechnology
|December 17, 2008
Summary
The development of monoclonal antibodies (mAbs) requires careful consideration of manufacturing processes, as small changes can impact efficacy and safety. Non-clinical data are crucial for risk identification and ensuring clinical trial safety for these advanced therapeutics.
Area of Science:
- Biotechnology and Pharmaceutical Sciences
- Immunology and Therapeutics
Background:
- Monoclonal antibodies (mAbs) have evolved from murine to humanized and fully human forms for therapeutic use.
- Manufacturing processes can introduce heterogeneity (e.g., glycosylation) in mAbs, affecting product quality and clinical outcomes.
- Quality, non-clinical, and clinical data are interconnected and influence each other.
Purpose of the Study:
- To highlight the evolving landscape of monoclonal antibody development.
- To emphasize the critical link between manufacturing, non-clinical data, and clinical safety/efficacy.
- To discuss regulatory considerations for monoclonal antibody clinical trials.
Main Methods:
- Review of structural evolution of monoclonal antibodies.
- Analysis of the impact of manufacturing processes on mAb heterogeneity.
- Examination of non-clinical data requirements for toxicity evaluation in relevant species.
- Discussion of regulatory guidelines for clinical trials, including risk identification and mitigation.
Main Results:
- Monoclonal antibodies, despite being monoclonal, exhibit heterogeneity impacting product quality.
- Non-clinical data are essential for proactive risk identification and demonstrating species relevance.
- Recent incidents have influenced regulatory approaches, leading to specific guidelines for early-phase trials.
- Enhanced safety measures may be needed for pivotal trials due to mAb half-life and mechanism of action.
Conclusions:
- Robust quality control and comprehensive non-clinical evaluation are vital for safe and effective monoclonal antibody therapeutics.
- Regulatory frameworks are adapting to address the unique challenges of monoclonal antibody development and clinical application.
- Continuous monitoring and risk mitigation strategies are essential throughout the lifecycle of monoclonal antibody products.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...